Category: Pharma Industry

Daiichi-Sankyo Offering Refunds for 340B Overcharges on Two Drugs

In Federal, Pharma IndustryApril 25, 2023335 Views

Daiichi-Sankyo is offering refunds for 340B overcharges on its breast cancer drug Enhertu and cholesterol drug Welchol for Oral Suspension.

Drug manufacturer Daiichi-Sankyo is offering 340B covered entities refunds for overcharges on metastatic breast cancer treatment Enhertu during Q1 2020 and on cholesterol medication Welchol for Oral Suspension during Q1 2022 and Q4 2022.

The U.S. Health Resources

…

Lilly Asks Covered Entity to Promptly Repay “Duplicate 340B/Medicaid Discounts”

In Federal, Pharma Industry, RegulatoryApril 18, 20231374 Views

Tom Mirga

Lilly has asked a 340B covered entity to promptly repay it for “duplicate 340B/Medicaid discounts."

Drug manufacturer Eli Lilly asked a 340B covered entity last week to promptly repay it for “duplicate 340B/Medicaid discounts” and evaluate all Lilly prescriptions that it or its contract pharmacies dispensed for the last three years.

Consultants and

…

HHS OIG and HRSA Are Mum About 340B Manufacturer Civil Monetary Penalties and Violation Notices

In Federal, Pharma Industry, RegulatoryApril 13, 2023643 Views

Tom Mirga

screenshot of HRSA correspondence to stakeholders web page

HRSA and OIG have no comment on the status of drug manufacturer civil monetary penalties and violation letters stemming from denials of 340B pricing to covered entities that use contract pharmacies.

The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing

…

AHA Again Blasts PhRMA and NACHC’s Alliance to Remake 340B

In Pharma Industry, ProvidersApril 11, 2023554 Views

Tom Mirga

The AHA slammed PhRMA and NACHC's 340B reform alliance again, this time in its blog and related talking points.

The American Hospital Association has again blasted the drug industry’s alliance with community health centers for 340B reform, calling it “another misguided attempt by drug companies to dismantle [340B] so that they can continue to pad their billion-dollar

…

Novartis to Appeals Court: Our New 340B Contract Pharmacy Policy Doesn’t Affect Our Case Before You

In Federal, Judicial, Pharma IndustryApril 6, 2023964 Views

Tom Mirga

Novartis told a federal appeals court its revised 340B contract pharmacy policy doesn't affect its 340B contract pharmacy case awaiting the court’s decision.

Drug maker Novartis told a federal appeals court in Washington, D.C. Tuesday its revised 340B contract pharmacy policy “does not impact the legal arguments at issue” in its 340B contract pharmacy case awaiting the court’s decision.

If the

…

Novartis Toughens its Conditions on 340B Pricing for Hospitals

In News Alert, Pharma IndustryApril 3, 20232176 Views

Tom Mirga

Novartis announced today that it will let hospitals without an in-house pharmacy pick just one contract pharmacy location where Novartis will ship 340B discounted drugs.

Drug manufacturer Novartis this afternoon significantly beefed up its conditions on 340B pricing for hospitals.

Two others—GlaxoSmithKline and Pfizer—made similar moves on Friday. Novartis is the sixth to stiffen its 340B pricing policy since a federal appeals

…

GSK Extends 340B Pricing Conditions to all Covered Entities and all Products

In Breaking, Pharma IndustryMarch 31, 20233083 Views

Tom Mirga

GSK today extened its conditions on 340B pricing to all covered entities and all of its products.

UPDATE Friday, March 31, 2023, 6:45 p.m. EDT—Story updated with comment from the National Association of Community Health Centers.

Drug manufacturer GlaxoSmithKline this afternoon announced a major expansion of its conditions on 340B pricing in

…

Pfizer Is the Second Drug Maker This Week to Tighten Limits on 340B Sales to Hospitals

In News Alert, Pharma IndustryMarch 31, 20231435 Views

Tom Mirga

Drug manufacturer Pfizer stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz.

Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.

Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for

…

ASAP 340B Hires Executive Director and Publishes FAQ in Response to Questions and Criticism

In Pharma Industry, ProvidersMarch 30, 20231255 Views

Tom Mirga

ASAP 340B this week announced it hired an executive director and published an FAQ that responds to questions and criticism.

ASAP 340B, the nonprofit group that the drug industry and health centers formed to help advance their joint plan to remake the 340B program, has hired an executive director and published an FAQ that responds to questions and

…

AIDS Healthcare Foundation Protests Against PhRMA/NACHC Alliance During 340B Coalition Conference

In Pharma Industry, ProvidersMarch 30, 2023733 Views

Tom Mirga

Protesters carry placards in support of the 340B drug pricing program and AHF

AIDS Healthcare Foundation held a protest march Tuesday at the 340B Coalition winter conference in California against the PhRMA/NACHC alliance to change the 340B program.

AIDS Healthcare Foundation held two demonstrations Tuesday—one outdoors and loud, the other indoors and silent—at the 340B Coalition winter conference in California to protest against the new drug industry/community health center alliance to change the 340B program.

“Let’s

…

News Alert

Breaking News

News Alert

Site Footer